Pfizer explores rare disease path

The world’s largest pharmaceutical company is thinking small by setting up a dedicated rare disease R&D unit in Cambridge, Massachusetts. Pfizer’s new group, announced in June, will focus initially on treatments for muscular dystrophy and other serious diseases caused by genetic mutations, in addition to hemophilia, for which the company already markets a treatment. Pfizer’s incursion into rare diseases is the latest signal that businesses built around niche indications are no longer the exclusive domain of biotech enterprises, such as Cambridge, Massachusetts–based Genzyme. The New York–based pharma company now joins Merck, of Whitehouse Station, New Jersey, GlaxoSmithKline (GSK) of London and Novartis of Basel, all of which have initiated rare disease programs in recent years. Whether such initiatives will remain small in scale—as part of numerous initiatives under way in big pharma to diversify their businesses—or expand to such an extent that they rival programs at biotech companies that have traditionally targeted rare disease is an open question.

“[Pharma] companies are realizing that for niche diseases, you can charge a significant premium,” says Simos Simeonidis, managing director senior biotechnology analyst Rodman & Renshaw. Patient numbers are small by pharma standards, but because the drugs are lifesaving, even though they are expensive, insurers must pay up. Investors and corporate decision makers are slowly waking up to the potential value of these drugs that some have started calling ‘minibusters.’

In February, GSK announced plans to form a new stand-alone rare diseases unit. The new unit, described in a company release as operating under a “lean structure,” will work with the company’s existing capabilities and seek strategic collaborations with other companies. Analysts, however, have been reserved in their assessments of these initiatives, noting that many of them are very small, resembling almost a token effort, rather than a full commitment to rare disease research. Indeed, Pfizer’s new initiative, still in its very earliest stages, consists of two employees and a few laboratory benches.

But with the price incentive, rare disease research programs represent a good opportunity. Simeonidis gives Alexion’s first product Soliris (eculizumab), approved for treating paroxysmal nocturnal hemoglobinuria, as an example. The average price for the lifesaving drug developed by the Cheshire, Connecticut–based company, is roughly $400,000 a year, and insurance companies are paying for it. At the same time, insurance companies in some countries are refusing to pay for drugs like Avastin (bevacizumab), which costs $50,000–$100,000 per year, that may extend life by a couple of months (this issue, page 879).

Tax incentives and seven years’ protection against competition, spelled out in the Orphan Drug Act of 1983, encouraged biotech companies to pursue rare diseases or orphan indications. In previous decades, such niche markets were considered too small for multinational pharmaceutical companies that had large marketing arms to drive billion dollar sales of drugs for common ailments in the general population. But as a singular pursuit of the blockbuster model and me-too drugs becomes unsustainable, pharma companies are looking more closely at niche opportunities. What’s more, an advantage of a more scientific nature is also beginning to attract large players. As rare diseases are typically caused by a known genetic variant, on paper at least, developing a cure should be more straightforward than for many common, multifactorial diseases with mass markets, such as type 2 diabetes.

“The progress that’s been made in genetically describing many of these diseases allows us to be [in a better position] to find drugs that can work for the diseases,” says Ed Mascioli, vice president, biotherapeutics R&D, orphan and genetic diseases for Pfizer.

The scientific rationale is strengthening risk-benefit calculations and pharma are jumping on board. Damien Conover, a senior stock analyst...
**IN brief**

**Provenge twists again**

Just when Dendreon thought it had reached the promised land, with the approval of its prostate cancer vaccine Provenge (sipuleucel-T), the Seattle-based company is back in the hot seat. In July, the Center for Medicare and Medicaid Services (CMS), which oversees Medicare, announced an investigation into whether it should pay for the cancer vaccine, approved in April (*Nat. Biotechnol.* 28, 531–532, 2010). It sounds fair that a treatment regime costing $93,000 that offers 4 months’ increase in median survival should be under such scrutiny, especially given that 75% of the potential patients, by Dendreon’s reckoning, would be covered by Medicare. Yet, Dendreon consultant Jayson Slotnik of Foley Hoag in Washington, D.C. points out that this kind of analysis is rarely undertaken so soon after approval. “What new data will they be looking at?” he asks. CMS will not discuss an ongoing investigation, leaving to conjecture the reason for their decision to pursue this course. In a letter to CMS, Dendreon requests that the investigation be abandoned or, at the least, brought to a speedy conclusion (the process takes a year) based on consistent results from four clinical trials, which recently appeared in the *New England Journal of Medicine*. Even that did not go smoothly, as an accompanying editorial questioned aspects of the trials. Meanwhile, on August 6, the FDA issued a warning to Dendreon about misleading promotions.

**Lilly snaps up Alnara**

Eli Lilly of Indianapolis, has acquired Alnara Pharmaceuticals, a two-year-old startup with a single drug—an enzyme supplement—currently under review by the US Food and Drug Administration. Alnara’s lead product, Trizytek (liprotamase), is a nonporcine pancreatic enzyme therapy for patients with cystic fibrosis and other conditions in which the pancreas fails to produce enough enzymes needed to digest and absorb food. With the new deal, Lilly will gain a foothold in the enzyme replacement market, whereas the Cambridge, Massachusetts–based Alnara will benefit from the larger company’s experience in the US, particularly in regulatory affairs, to help steer Trizytek into the clinic.

“The deal sits with Lilly’s new strategy of looking for niche markets where there are low levels of competition and less likelihood of pricing pressure,” observes William Kridel, managing director of specialist investment banking group Ferghana Partners in New York. Kridel adds that Lilly may go on to do other such specialty deals. Trizytek contains protease, amylase and lipase enzymes made by microbial processes, and will be offered as an alternative to existing products made with pig enzymes. Alnara hopes to have the product on the market late this year. Trizytek once belonged to Altus Pharmaceuticals, which folded following the recent economic downturn. Altus transferred rights to liprotamase to the Cystic Fibrosis Foundation Therapeutics, which were then repurchased by Alnara. The terms of the deal were not disclosed.

Laura DeFrancesco

for Morningstar, points out that “what Pfizer is doing with their new rare disease unit is similar to what we’re seeing at GlaxoSmithKline and what we’ve already seen at Novartis. It is a little bit emblematic of what we’re seeing across the industry, which is a shift toward rare diseases, away from the primary care model that had served the big pharmaceutical firms pretty well over the last couple of decades.”

Until now, success stories in rare diseases have been the province of small biotech. BioMarin, of Novato, California, for example, has three drugs on the market, all approved for rare disease indications: Naglazyme (galsulfase) for the treatment of mucopolysaccharidosis VI (MPS VI), Aldurazyme (laronidase) for MPS I and Kuvan (sapropterin dihydrochloride) for phenylketonuria. Elsewhere, Brussels-based chemical company Solvay succeeded with Creon, its pancreatic lipase therapy for cystic fibrosis, which led to its acquisition by Abbott Laboratories of Abbott Park, Illinois. And since 1994, Genzyme has enjoyed a monopoly on Gaucher disease treatment with its drug Cerezyme.

Although one of the advantages for biotech companies that have traditionally targeted orphan disease indications has been the lack of competition from big pharma, the entry of multinatinal drug companies into the area might not be all bad news. According to Simeonidis, many biotech companies have steered away from rare diseases because investors have preferred to emphasize larger markets, which they perceived as providing greater product returns and being more attractive for a potential pharma buyout. Simeonidis believes that having big pharma in the sandbox could be immensely helpful for biotech companies seeking investor support for rare disease indications. And of course, playing with big pharma companies translates to increased opportunities for partnerships, licensing agreements and acquisitions.

Competition from pharma will affect mostly biotech, analyst Conover believes. Genzyme is currently the prime example of a biotech company that, in the long term, may experience competitive pressure, as the new Pfizer rare disease unit will be focusing on Gaucher disease. Since 1994 Genzyme has offered the only effective therapy for Gaucher disease. Simeonidis thinks Pfizer will find it hard to compete with Genzyme at least in the near term. “If you look three to five years down the line, you could see a company like Pfizer having an advantage over Genzyme in this arena because of the difference in the amount of resources available... but right now, I would not think a company like Biomarin or Genzyme would be threatened by the presence of Pfizer.”

Catherine Shaffer

Ann Arbor, Michigan